Quick Answer
Grace Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $22.13 million for the year ending 2025.
- Grace Therapeutics, Inc. showed a decrease of -3.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $12.12 million | Q3 2020: $11.55 million | Q4 2020: $26.55 million | Q2 2021: $40.98 million | Q3 2021: $36.93 million | Q4 2021: $33.01 million | Q2 2022: $38.38 million | Q3 2022: $34.93 million | Q4 2022: $26.24 million | Q2 2023: $21.63 million | Q3 2023: $26.99 million | Q4 2023: $18.55 million | Q2 2024: $19.39 million | Q3 2024: $15.16 million | Q4 2024: $11.06 million | Q1 2025: $22.13 million | Q2 2025: $20.01 million | Q3 2025: $16.86 million | Q4 2025: $18.67 million.
- Over the full 9 years of available data (2018 to 2025), Grace Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 244.6%.
- Historical annual values: Fiscal year 2025: $22.13 million | Fiscal year 2024: $23.01 million | Fiscal year 2023: $27.88 million | Fiscal year 2022: $30.34 million | Fiscal year 2021: $50.94 million | Fiscal year 2020: $14.24 million | Fiscal year 2019: $16.87 million | Fiscal year 2019: $16.87 million | Fiscal year 2018: $6.42 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: